Canon has announced the EF 35mm F1.4L II USM, the second generation of its popular wide-angle prime. It uses newly-designed Blue Spectrum Refractive Optics, which claim to correct chromatic aberration better than any other existing technology.
The 35mm F1.4L II includes a total of 14 elements, two of which are aspherical and the other being ‘Super UD’. It offers 9 aperture blades for pleasing…
Corden found Martin trying to hitch a ride to San Francisco – where Coldplay is rocking the Super Bowl 50 halftime show – and after begrudgingly agreeing to give the front man a lift, the two embarked on a 400-mile road trip that was one of the most adorable things ever.
If you didn’t like Martin before, there’s no way you won’t fall in love with the 38-year-old singer after this. From not understanding even the most basic aspects of “American football” to the humble, unassuming way he buys lemonade from some kids on the side of the road, Martin seems like he’d be the absolute best road trip buddy.
Perhaps the most touching moment of the whole bit came when Martin busted out his mini electric keyboard – which he said is the instrument he’d be using at the upcoming halftime show – and delivered a heartwarming tribute to David Bowie.
Serenading Corden, Martin performed a low-fi rendition of Bowie’s 1977 hit “"Heroes,”“ that got the guys kind of misty eyed.
"Oh! Great song,” Corden beamed.
“Thanks, Dave,” Martin added, saluting the late music icon who died on Jan. 10 after an 18-month battle with cancer.
What set this “Carpool Karaoke” apart from past segments – like Adele’s rap-filled romp – is the massive scope. Unlike Corden’s previous goofy adventures around Hollywood, this time the two entertainers really did embark on an epic, long-distance road trip.
That meant bunking up in a motel, which, of course, lead to the two in spooning in a twin bed while wearing flannel pajamas and singing Coldplay’s “Fix You.”
Producers are “Straight Outta Compton” producer Matt Alvarez, “Master of None” star Lena Waithe and Benjamin Cory Jones.
Stone will direct “Ain’t No Half Steppin'” from a script by Chuck Hayward, who currently writes for Cooper Barrett’s “Guide to Surviving Life” on Fox. The story centers on an ambitious black sorority girl who, in order to get admitted to the law school of her dreams, agrees to cross culture lines and teach the exclusive art of black Greek stepping to a band of white sorority girls whose charter is about to be revoked.
Alvarez joined the studio’s development and production team in October in an exclusive production pact.
Aakomon Jones, whose credits include the “Pitch Perfect” franchise, “Get on Up” and “Dreamgirls,” will choreograph the film.
Broad Green Pictures will distribute the film theatrically in the U.S. Casting is currently under way.
Las previsiones de eBay para 2016 incumplen las expectativas
(Reuters) - La compañía de comercio electrónico eBay estimó unos ingresos y beneficios menores de lo esperado para el actual trimestre y para todo el año, lo que hizo que las acciones de la empresa cayeran casi un 10 por ciento en las operaciones posteriores al cierre.
La firma estimó un beneficio ajustado para el primer trimestre de entre 43 a 45 centavos por acción e ingresos de entre 2.050 millones a 2.100 millones de dólares.
Analistas esperaban en promedio una ganancia de 48 centavos por acción y ventas de 2.160 millones de dólares, según Thomson Reuters I/B/E/S.
EBay proyectó un beneficio ajustado para todo el año de entre 1,82 a 1,87 dólares por acción e ingresos por entre 8.500 millones a 8.800 millones de dólares, también por debajo de las previsiones de analistas.
La compañía, que se enfrenta a una dura competencia en el sector de comercio electrónico de su rival Amazon.com y de minoristas tradicionales, también dijo que las ventas no crecieron en el trimestre de las fiestas de fin de año.
La empresa, que obtiene cerca de un 60 por ciento de sus ingresos desde el extranjero, también afronta dificultades por la apreciación del dólar.
Las ventas de eBay alcanzaron los 2.320 millones de dólares en el cuarto trimestre, que terminó el 31 de diciembre, estables respecto al año previo y en línea con las estimaciones de analistas.
El beneficio neto cayó a 477 millones de dólares, o 39 centavos por acción, desde 1.020 millones de dólares, ó 82 centavos por acción.
iHeartRadio Music Awards Adds Dance Artist of the Year Category
Dance music is at the pop culture forefront, so it only makes sense that a dance artist of the year category has been added to he iHeartRadio Music Awards.
Zedd Says He’ll &lsquoMove Back to Germany’ If Donald Trump Is President
The nominees include Calvin Harris, David Guetta, Major Lazer, Skrillex & Diplo and Zedd. A few of these nominees also grabbed nods in the categories for dance song of the year and best collaboration. Dynamic duo Disclosure is up for best cover song following their “Hotline Bling” collab with Sam Smith.
David Guetta featuring Nicki Minaj, Bebe Rexha & Afrojack — “Hey Mama”Major Lazer & DJ Snake featuring MØ — “Lean On”Mr. Probz — “Waves”Skrillex & Diplo with Justin Bieber — “Where Are Ü Now?”DJ Snake & AlunaGeorge — “You Know You Like It”
Best Collaboration *Socially Voted Category
Taylor Swift featuring Kendrick Lamar — “Bad Blood”Meghan Trainor featuring John Legend — “Like I’m Gonna Lose You”Wiz Khalifa featuring Charlie Puth — “See You Again”Mark Ronson featuring Bruno Mars — “Uptown Funk”Skrillex & Diplo with Justin Bieber — “Where Are Ü Now?”
Best Cover Song (New Category) *Socially Voted Category
Ryan Adams covering Taylor Swift — 1989 (Album in Full)Alessia Cara covering Taylor Swift — “Bad Blood”Kelly Clarkson covering Rihanna — “Bitch Better Have My Money”Pentatonix covering Omi — “Cheerleader”Troy Sivan covering Selena Gomez And Justin Bieber — “Hands To Myself/Sorry”Demi Lovato covering Adele — “Hello”Justin Bieber covering Drake — “Hotline Bling”Sam Smith & Disclosure covering Drake — “Hotline Bling”Ed Sheeran covering Fetty Wap — “Trap Queen”Fifth Harmony, Jasmine V, Jacob Whitesides and Mahogany Lox covering Mark Ronson featuring Bruno Mars — “Uptown Funk”
World's top golfer Jordan Spieth looking for win with country singer Jake Owen at Pebble Beach Pro-Am
Refreshed after a globetrotting run of tournaments that took him from Hawaii to Abu Dhabi and then Singapore, Jordan Spieth returns to the PGA Tour with high hopes for this week’s Pebble Beach National Pro-Am in California. The American world No1 has finished no worse than joint seventh in his last seven starts worldwide while winning twice, and relishes competing in the pro-am celebrity event on the picturesque Monterey Peninsula.
“As much fun as we’re having in between shots I’m here to win this golf tournament,” Masters and US Open champion Spieth, 22, said at a news conference on 10 February, while preparing for the opening round.
Spieth tied for fifth at the Abu Dhabi HSBC Golf Championship and finished second at the Singapore Open in his last two starts, and is looking forward to this week when his amateur partner will be American country music singer Jake Owen.
“Even if the rounds are a bit longer because you have foursomes you’re still having more fun, you feel like you’re playing a team event while still kind of grinding yourself,” said the Texan.
Owen, who has played with Spieth for the last three years at Pebble Beach, joined Spieth at the news conference and was asked about playing with the world’s top-ranked player. Owen responded with a story from when Spieth and Owen played in December 2014 at a charity golf event in Florida.
“He looks at me and says ‘Alright, what are the odds I’m going to make this?’ I’m like 'You’re like 98 yards out in the middle of the fairway’ and without missing it he just steps up, hits the shot, in the air, he’s like, 'Pay up’. And I’m sitting there watching it, it hits three feet behind the pin, with all these people watching, spins back and goes in the hole. He looks at me and I’m like, this doesn’t happen with normal people!” Owen said.
Spieth heads a strong field this week that features five other players ranked in the world’s top 10, including Australian Jason Day (third), American Bubba Watson (sixth) and England’s Justin Rose (seventh).
Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–
Squibb Company (BMY) and Pfizer
Inc. (PFE) today announced that the companies have entered into
a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq:
PTLA) to develop and commercialize the investigational agent andexanet
alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development
in the U.S. and Europe, is designed to reverse the anticoagulant
activity of Factor Xa inhibitors, including Eliquis (apixaban).
“We are committed to reducing the risk of stroke in nonvalvular atrial
fibrillation patients and treating deep vein thrombosis and pulmonary
embolism,” said Douglas Manion, M.D., head of Specialty Development,
Bristol-Myers Squibb. “Bristol-Myers Squibb and Pfizer’s agreement with
Portola is an important step forward toward the goal of delivering the
first reversal agent for Factor Xa inhibitors, including Eliquis, to
patients in Japan. The ability to reverse the anticoagulation effect of Eliquis
and other Factor Xa inhibitors may be helpful for some patients who
experience a major bleeding event or require emergency surgery while on Eliquis
or another Factor Xa inhibitor.”
“This agreement in Japan is another great example of the alliance’s
commitment to the patients we serve. Eliquis has proven to be an
important treatment option for patients at risk for stroke and blood
clots due to nonvalvular atrial fibrillation and for the treatment of
deep vein thrombosis and pulmonary embolism, but currently there is no
approved reversal agent,” said Rory O’Connor, M.D., senior vice
president and head of Global Medical Affairs, Global Innovative
Pharmaceuticals Business, Pfizer Inc. “With our partner, Bristol-Myers
Squibb, we look forward to working with Portola to develop andexanet
alfa as a reversal agent for Eliquis in Japan.”
Under the terms of the agreement, Portola will receive an upfront
payment of $15 million, potential regulatory milestones of $20 million
and sales-based milestones of $70 million as well as compensation based
on andexanet alfa net sales. Bristol-Myers Squibb and Pfizer will
co-fund with Portola the development and commercialization of andexanet
alfa in Japan. Portola will retain rights to andexanet alfa outside of
Japan and remain responsible for the manufacturing supply.
This agreement builds on the companies’ existing clinical collaboration
to develop andexanet alfa in the U.S. and Europe. In December 2015,
Portola announced it had completed the submission of a Biologics License
Application to the U.S. Food and Drug Administration (FDA) for andexanet
alfa and was awaiting acceptance for filing. The FDA assigned a PDUFA
date of August 17, 2016, under an Accelerated Approval pathway. Portola
has stated that it plans to submit an EU application in 2017.
About Andexanet Alfa
Andexanet alfa, an investigational drug, is a modified human Factor Xa
molecule that acts as a decoy to target and sequester with high
specificity both oral and injectable Factor Xa inhibitors in the blood.
Once bound, the Factor Xa inhibitors are unable to bind to and inhibit
native Factor Xa, thus allowing for the restoration of normal hemostatic
processes. Andexanet alfa is the only compound being studied as a
reversal agent for Factor Xa inhibitors that directly and specifically
corrects anti-Factor Xa activity – the anticoagulant mechanism of these
Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By
inhibiting Factor Xa, a key blood clotting protein, Eliquis
decreases thrombin generation and thus blood clot formation. Eliquis is
a prescription medicine approved for multiple indications in the United
States, the European Union (which includes 28 member states plus Iceland
and Norway) and Japan, as well as a number of other countries around the
world based on efficacy and safety data, including results from seven
Phase 3 clinical trials. In Japan, Eliquis is approved for the
prevention of stroke and systemic embolism in patients with nonvalvular
atrial fibrillation (NVAF). Eliquis is also approved in Japan for
the treatment of venous thromboembolism (VTE), which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE), and prevention of
recurrent DVT and PE following initial therapy.
ELIQUIS Important Safety Information and
ELIQUIS Important Safety Information
Active pathological bleeding
Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic
WARNINGS AND PRECAUTIONS
Increased Risk of Thrombotic Events after Premature
Discontinuation: Premature discontinuation of any oral
anticoagulant, including ELIQUIS, in the absence of adequate
alternative anticoagulation increases the risk of thrombotic events.
An increased rate of stroke was observed during the transition from
ELIQUIS to warfarin in clinical trials in atrial fibrillation
patients. If ELIQUIS is discontinued for a reason other than
pathological bleeding or completion of a course of therapy, consider
coverage with another anticoagulant.
Bleeding Risk: ELIQUIS increases the risk of bleeding and can
cause serious, potentially fatal, bleeding.
Concomitant use of drugs affecting hemostasis increases the risk
of bleeding, including aspirin and other antiplatelet agents,
other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs,
Advise patients of signs and symptoms of blood loss and to report
them immediately or go to an emergency room. Discontinue ELIQUIS
in patients with active pathological hemorrhage.
There is no established way to reverse the anticoagulant effect of
apixaban, which can be expected to persist for at least 24 hours
after the last dose (i.e., about two half-lives). A specific
antidote for ELIQUIS is not available.
Spinal/Epidural Anesthesia or Puncture: Patients treated with
ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop
an epidural or spinal hematoma which can result in long-term or
The risk of these events may be
increased by the postoperative use of indwelling epidural catheters or
the concomitant use of medicinal products affecting hemostasis.
Indwelling epidural or intrathecal catheters should not be removed
earlier than 24 hours after the last administration of ELIQUIS. The
next dose of ELIQUIS should not be administered earlier than 5 hours
after the removal of the catheter. The risk may also be increased by
traumatic or repeated epidural or spinal puncture. If traumatic
puncture occurs, delay the administration of ELIQUIS for 48 hours.
patients frequently and if neurological compromise is noted, urgent
diagnosis and treatment is necessary. Physicians should consider the
potential benefit versus the risk of neuraxial intervention in ELIQUIS
Prosthetic Heart Valves: The safety and efficacy of ELIQUIS
have not been studied in patients with prosthetic heart valves and is
not recommended in these patients.
Acute PE in Hemodynamically Unstable Patients or Patients who
Require Thrombolysis or Pulmonary Embolectomy: Initiation of
ELIQUIS is not recommended as an alternative to unfractionated heparin
for the initial treatment of patients with PE who present with
hemodynamic instability or who may receive thrombolysis or pulmonary
The most common and most serious adverse reactions reported with
ELIQUIS were related to bleeding.
TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS
ELIQUIS should be discontinued at least 48 hours prior to elective
surgery or invasive procedures with a moderate or high risk of
unacceptable or clinically significant bleeding. ELIQUIS should be
discontinued at least 24 hours prior to elective surgery or invasive
procedures with a low risk of bleeding or where the bleeding would be
noncritical in location and easily controlled. Bridging
anticoagulation during the 24 to 48 hours after stopping ELIQUIS and
prior to the intervention is not generally required. ELIQUIS should be
restarted after the surgical or other procedures as soon as adequate
hemostasis has been established.
Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of
cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) increase
exposure to apixaban and increase the risk of bleeding. For patients
receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose
of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are
strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole,
itraconazole, ritonavir, or clarithromycin). In patients already
taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with
strong dual inhibitors of CYP3A4 and P-gp.
Strong Dual Inducers of CYP3A4 and P-gp: Avoid concomitant use
of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g.,
rifampin, carbamazepine, phenytoin, St. John’s wort) because such
drugs will decrease exposure to apixaban and increase the risk of
stroke and other thromboembolic events.
Anticoagulants and Antiplatelet Agents: Coadministration of
antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic
NSAID use increases the risk of bleeding. APPRAISE-2, a
placebo-controlled clinical trial of apixaban in high-risk post-acute
coronary syndrome patients treated with aspirin or the combination of
aspirin and clopidogrel, was terminated early due to a higher rate of
bleeding with apixaban compared to placebo.
PREGNANCY CATEGORY B
There are no adequate and well-controlled studies of ELIQUIS in
pregnant women. Treatment is likely to increase the risk of hemorrhage
during pregnancy and delivery. ELIQUIS should be used during pregnancy
only if the potential benefit outweighs the potential risk to the
mother and fetus.
Please see full Prescribing Information, including BOXED WARNINGS and
Medication Guide, available at www.bms.com.
Indications in the United States
ELIQUIS is indicated to reduce the risk of stroke and systemic embolism
in patients with nonvalvular atrial fibrillation.
ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT),
which may lead to pulmonary embolism (PE), in patients who have
undergone hip or knee replacement surgery.
ELIQUIS is indicated for the treatment of DVT and PE, and to reduce the
risk of recurrent DVT and PE following initial therapy.
About the Bristol-Myers Squibb/Pfizer Collaboration
In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide
collaboration to develop and commercialize apixaban, an oral
anticoagulant discovered by Bristol-Myers Squibb. This global alliance
combines Bristol-Myers Squibb’s long-standing strengths in
cardiovascular drug development and commercialization with Pfizer’s
global scale and expertise in this field.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information, please
visit www.bms.com or
follow us on Twitter at http://twitter.com/bmsnews.
About Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, Pfizer has worked to make a difference for all who
rely on us. To learn more, please visit us at www.pfizer.com.
Bristol-Myers Squibb Forward Looking Statement
This press release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Among other risks, the compound described in this release is subject to
all the risks inherent in the drug development process, and there can be
no assurance that the development of this compound will be successful.
Forward-looking statements in the press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb’s
business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the
year ended December 31, 2014, its Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise.
Pfizer Disclosure Notice
The information contained in this release is as of February 1, 2016.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future
events or developments.
This release contains forward-looking information about Eliquis
(apixaban) and andexanet alfa, including their potential benefits, that
involves substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including, without
limitation, the ability to meet anticipated clinical trial commencement
and completion dates as well as the possibility of unfavorable clinical
data and additional analyses of existing clinical data; whether and when
any Biologics License Application (BLA) may be filed for andexanet alfa;
whether and when regulatory authorities will approve any such BLA;
decisions by regulatory authorities regarding label and andexanet alfa;
and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2014 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov